Cytodyn Inc
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colo… Read more
Cytodyn Inc (CYDY) - Total Liabilities
Latest total liabilities as of November 2025: $128.68 Million USD
Based on the latest financial reports, Cytodyn Inc (CYDY) has total liabilities worth $128.68 Million USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cytodyn Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Cytodyn Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cytodyn Inc Competitors by Total Liabilities
The table below lists competitors of Cytodyn Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samhyun
KQ:437730
|
Korea | ₩32.92 Billion |
|
Gorilla Technology Group Inc.
NASDAQ:GRRR
|
USA | $75.33 Million |
|
Citizens Financial Services Inc. Common Stock
NASDAQ:CZFS
|
USA | $2.73 Billion |
|
Yindu Kitchen Equipment Co Ltd
SHG:603277
|
China | CN¥1.84 Billion |
|
AnHui Annada Titanium Industry Co Ltd
SHE:002136
|
China | CN¥739.01 Million |
|
Dezhou United Petroleum Technology Co.Ltd.
SHE:301158
|
China | CN¥499.11 Million |
|
Beijing Bohui Innovation Technology Co Ltd
SHE:300318
|
China | CN¥2.04 Billion |
|
ShenZhen Zero-Seven Co Ltd
SHE:000007
|
China | CN¥173.46 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Cytodyn Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 14.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytodyn Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytodyn Inc (2010–2025)
The table below shows the annual total liabilities of Cytodyn Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-05-31 | $114.09 Million | -10.79% |
| 2024-05-31 | $127.89 Million | +5.88% |
| 2023-05-31 | $120.79 Million | -2.26% |
| 2022-05-31 | $123.58 Million | -19.28% |
| 2021-05-31 | $153.10 Million | +188.89% |
| 2020-05-31 | $52.99 Million | +77.90% |
| 2019-05-31 | $29.79 Million | +64.97% |
| 2018-05-31 | $18.06 Million | +97.16% |
| 2017-05-31 | $9.16 Million | +155.78% |
| 2016-05-31 | $3.58 Million | -76.71% |
| 2015-05-31 | $15.37 Million | +241.21% |
| 2014-05-31 | $4.51 Million | +2.82% |
| 2013-05-31 | $4.38 Million | -13.13% |
| 2012-05-31 | $5.04 Million | -27.97% |
| 2011-05-31 | $7.00 Million | +20.99% |
| 2010-05-31 | $5.79 Million | -- |